Emerging trends in the pharmaceutical sector and Poolbeg Pharma’s strategic role

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Jeremy Skillington, the CEO of Poolbeg Pharma, will be presenting at the Cell & Gene Therapy International Europe 2024 event. His presentation will focus on a novel approach using p38 MAPK inhibition to prevent Cytokine Release

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma plc is a biopharmaceutical company dedicated to developing and commercialising innovative medicines that address significant unmet medical needs. The company actively seeks partners for its pipeline of ground-breaking programmes and is open to discussions

Liam Tremble, Principal Scientist at Poolbeg Pharma, is deeply involved in developing innovative treatments for diseases with significant unmet medical needs. His current work spans oncology, infectious diseases, and endocrinology, where he leads drug discovery efforts.

The medtech industry is at a crucial point, experiencing significant growth driven by the Covid-19 pandemic, which spurred a wave of innovation and investment. Though the sector has now returned to pre-pandemic growth trends, this transition

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for 2023. UCD, through its knowledge transfer

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Business & Finance, established in 1964, is celebrating its 60th anniversary this year. To mark this milestone, the publication is conducting a series of Leadership interviews with influential figures shaping Ireland’s corporate landscape. One of these

Artificial intelligence (AI) represents a sophisticated form of machine learning capable of swiftly analysing extensive datasets, uncovering non-obvious patterns, and pinpointing novel disease targets along with potential drugs. AI is increasingly influencing drug development by identifying

Poolbeg Pharma plc, a forward-thinking biopharmaceutical company, has recently garnered attention for its groundbreaking work with POLB001, a novel therapeutic candidate showing significant promise in clinical research. As an emerging player in the pharmaceutical industry, Poolbeg

A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design

Poolbeg Pharma, founded by Cathal Friel, operates with a distinct approach to funding and development. Friel, a renowned financier, has a track record of successfully launching and selling companies through Raglan Capital, his private equity vehicle.

Pharmaceutical giants like Merck KGaA are increasingly partnering with AI companies, signaling a trend in the drug development landscape where emerging technologies are adopted to expedite and improve the drug discovery process. AI promises faster and